^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CAT-179
i
Other names: CAT-179, HER2 CAR-NK Cell Therapy, HER2-targeted CAR-NK cell therapy
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Catamaran Bio
Drug class:
HER2 inhibitor
Related drugs:
1year
CAT-179, an allogeneic NK cell product expressing HER2-CAR, IL-15 and TGFβ dominant negative receptor, durably regresses HER2-expressing xenograft tumors in mice (AACR 2023)
Efficacy strongly correlated with the circulating levels of CAT-179, which significantly infiltrated the tumor xenograft. Our pre-clinical results demonstrate the potential of CAT-179 as a novel, durable, and off-the-shelf cell therapy to overcome the challenges associated with solid tumors and provide quantitative insights into pharmacokinetics, pharmacodynamics and anti-tumor activity of engineered NK cells expressing CAR, TGFb DNR and IL-15.
Preclinical
|
HER-2 (Human epidermal growth factor receptor 2) • TGFB1 (Transforming Growth Factor Beta 1) • IL15 (Interleukin 15)
|
HER-2 amplification • HER-2 expression
|
CAT-179
Share via
